-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Depreciation history and growth rate from Q1 2015 to Q1 2024.
- Adaptimmune Therapeutics PLC Depreciation for the quarter ending March 31, 2024 was $2.77M, a 67% increase year-over-year.
- Adaptimmune Therapeutics PLC annual Depreciation for 2023 was $9.45M, a 79.5% increase from 2022.
- Adaptimmune Therapeutics PLC annual Depreciation for 2022 was $5.27M, a 6.47% decline from 2021.
- Adaptimmune Therapeutics PLC annual Depreciation for 2021 was $5.63M, a 15% decline from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)